外照射放疗较根治性前列腺切除术增加膀胱癌风险:基于人群分析
该研究基于SEER-Medicare数据库84397例65岁以上局限性前列腺癌患者,比较根治性前列腺切除术(RP)与外照射放疗(EBRT)后第二原发膀胱癌(BCa)和直肠癌(RCa)风险。中位随访69个月,EBRT组5年和10年膀胱癌累积发生率均高于RP组,多因素竞争风险回归显示EBRT独立增加膀胱癌风险(HR 1.35,95%CI 1.18-1.55,p<0.001),但未增加直肠癌风险。
要点
- EBRT组10年膀胱癌累积发生率为2.34%,高于RP组的1.63%。
- EBRT独立增加第二原发膀胱癌风险(HR 1.35,95%CI 1.18-1.55,p<0.001)。
- EBRT与直肠癌风险无关(p=0.4)。
核心结论
- 接受EBRT的局限性前列腺癌患者较RP患者第二原发膀胱癌风险增加,但直肠癌风险无差异。
研究设计与样本
- 基于SEER-Medicare关联数据库的回顾性人群分析,纳入1988至2009年诊断的84397例65岁以上局限性前列腺癌患者。
- 33252例(39%)接受RP,51145例(61%)接受EBRT,中位随访69个月。
主要发现
- 共1660例发生盆腔肿瘤,其中膀胱癌1236例,直肠癌432例。
- RP组与EBRT组5年和10年膀胱癌累积发生率分别为0.75%(95%CI 0.64-0.85%)和1.63%(95%CI 1.45-1.80%) vs 1.26%(95%CI 1.15-1.37%)和2.34%(95%CI 2.16-2.53%)。
- RP组与EBRT组5年和10年直肠癌累积发生率分别为0.32%(95%CI 0.25-0.39%)和0.73%(95%CI 0.61-0.85%) vs 0.36%(95%CI 0.30-0.41%)和0.69%(95%CI 0.60-0.79%)。
- 多因素竞争风险回归显示EBRT与第二原发膀胱癌风险独立相关(HR 1.35,95%CI 1.18-1.55,p<0.001),与直肠癌风险无关(p=0.4)。
临床怎么用
- 对选择EBRT的前列腺癌患者,应告知第二原发膀胱癌风险增加,并在随访中关注膀胱癌筛查。
局限性
- 缺乏放疗剂量信息,且为回顾性研究,存在选择偏倚风险。
- 结果需通过设计良好的随机前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term survival can be achieved in patients affected by localized prostate cancer (PCa) treated with either radical prostatectomy (RP) or external beam radiotherapy (EBRT). However, development of a second primary tumor is still poorly investigated. OBJECTIVE: To investigate the impact of RP and EBRT on subsequent risk of developing bladder (BCa) and/or rectal cancer (RCa) among PCa survivors. DESIGN, SETTING, AND PARTICIPANTS: A total of 84397 patients diagnosed with localized PCa, treated with RP or EBRT between 1988 and 2009, and older than 65 yr of age were identified in the Surveillance, Epidemiology, and End Results Medicare insurance program-linked database. Our primary objective was to investigate the effect of EBRT and RP on the second primary BCa and RCa incidence. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable competing-risk regression analyses were performed to assess the risk of developing a second primary BCa or RCa. RESULTS AND LIMITATIONS: Of the 84397 individuals included in the study, 33252 (39%) were treated with RP and 51145 (61%) with EBRT. Median follow-up was 69 months, and follow-up periods for patients who did not develop BCa, RCa, or pelvic cancer were 68, 69, and 68 mo, respectively. A total of 1660 individuals developed pelvic tumors (1236 BCa and 432 RCa). The 5- and 10-yr cumulative BCa incidence rates were 0.75% (95% confidence interval [CI]: 0.64-0.85%) and 1.63% (95% CI: 1.45-1.80%) versus 1.26% (95% CI: 1.15-1.37%) and 2.34% (95% CI: 2.16-2.53%) for patients treated with RP versus EBRT, respectively. The 5- and 10-yr cumulative RCa incidence rates were 0.32% (95% CI: 0.25-0.39%) and 0.73% (95% CI: 0.61-0.85%) versus 0.36% (95% CI: 0.30-0.41%) and 0.69% (95% CI: 0.60-0.79%) for patients treated with RP versus EBRT, respectively. On multivariable competing risk regression analyses, treatment with EBRT was independently associated with the risk of developing a second primary BCa (hazard ratio: 1.35, CI: 1.18-1.55; p<0.001), but not RCa (p=0.4). Limitations include lack of information regarding the dose of radiotherapy and the retrospective nature with the implicit risk of selection bias. CONCLUSIONS: Patients treated with EBRT are at increased risk of developing a second primary BCa compared with those treated with RP. However, no differences were found considering RCa incidence in patients treated with RP or EBRT within the first 5 yr after primary therapy. These results need to be validated in a well-designed randomized prospective trial. PATIENT SUMMARY: We retrospectively analyzed the risk of developing a second primary bladder or rectal cancer during follow-up for patients treated with radical prostatectomy or external beam radiotherapy for a localized prostate cancer. We found that those treated with external beam radiotherapy are at an increased risk of developing a second primary bladder cancer tumor.
引用
- Moschini M, Zaffuto E, Karakiewicz PI, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol. 2018. PMID: 30293908. doi:10.1016/j.eururo.2018.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。